Davis Polk advised Solazyme, Inc. (SZYM) in connection with its concurrent SEC-registered offerings of 5,750,000 shares of common stock (which included 750,000 shares from the full exercise of the underwriters’ option to purchase additional shares) and an aggregate principal amount of $149.5 million of 5% convertible senior subordinated notes due 2019 (which included $19.5 million aggregate principal amount of notes from the full exercise of the underwriter’s over-allotment option). 

Goldman, Sachs & Co. and Morgan Stanley & Co. LLC acted as joint book-running managers and representatives of the several underwriters for the common stock offering. Goldman, Sachs & Co. acted as sole underwriter for the convertible notes offering. 

Based in South San Francisco, California, Solazyme is a renewable oil and bioproducts company that transforms a growing range of abundant plant-based sugars into high-value triglyceride oils and other bioproducts. 

The Davis Polk capital markets team included partner Alan F. Denenberg, counsel Jeffrey Gould, and associates Katherine Tsai and Jason Bassetti. Partner Rachel D. Kleinberg and associates Catherine Paskoff Chang and Patrick E. Sigmon provided tax advice. Counsel Catherine L. Martin and Marcie Goldstein provided Investment Company Act advice and FINRA advice, respectively. Members of the Davis Polk team are based in the Menlo Park, New York and Washington DC offices.